EnglishGermanRomanian

European Commission Grants AbbVie’s MAVIRET® (glecaprevir/pibrentasvir) Marketing Authorization for the Treatment of Chronic Hepatitis C in All Major Genotypes (GT1-6)

European Commission Grants AbbVie’s MAVIRET® (glecaprevir/pibrentasvir) Marketing Authorization for the Treatment of Chronic Hepatitis C in All Major Genotypes (GT1-6)

– MAVIRET is a new 8-week, pan-genotypic treatment for hepatitis C patients without cirrhosis and who are new to treatment* 
– Marketing authorization is supported by 97.5 percent cure** rate across this group of patients(1)
– MAVIRET is a pan-genotypic treatment approved for use in patients across all stages of chronic kidney disease(1) 
– AbbVie’s investigational, pan-genotypic HCV treatment is also under Priority Review by the U.S. FDA

NORTH CHICAGO, Ill.July 28, 2017 /PRNewswire/ — AbbVie (NYSE: ABBV), a global biopharmaceutical company, today announced that the European Commission has granted marketing authorization for MAVIRET® (glecaprevir/pibrentasvir), a once-daily, ribavirin-free treatment for adults with chronic hepatitis C virus (HCV) infection across all major genotypes (GT1-6). MAVIRET is a new 8-week, pan-genotypic treatment for patients without cirrhosis and who are new to treatment,* who comprise the majority of the 71 million people living with HCV globally.2,3

„MAVIRET represents an innovation in HCV care as an 8-week, pan-genotypic option that combines two distinct antiviral agents and has high efficacy even against most genotypes commonly associated with resistance to treatment,” said Michael Severino, M.D., executive vice president, research and development and chief scientific officer, AbbVie. „This new treatment advancement has the potential to meet the diverse needs of patients in as short as 8 weeks across Europe.”

Articol Original – https://news.abbvie.com/news/european-commission-grants-abbvies-maviret-glecaprevirpibrentasvir-marketing-authorization-for-treatment-chronic-hepatitis-c-in-all-major-genotypes-gt1-6.htm

2017-08-10T05:32:52+00:00